Nov 7, 2025 08:02AM Atea presents hepatitis C drug data showing 7-8 week cure potential

Aug 7, 2025 04:09PM Aviragen Therapeutics (AVIR) Misses Q2 EPS by 3c

Jun 24, 2025 07:00AM Atea Pharmaceuticals Inc. (AVIR) Announces Continued Advancement of Global Phase 3 HCV Program

May 12, 2025 04:54PM Aviragen Therapeutics (AVIR) Tops Q1 EPS by 1c

May 7, 2025 07:00AM Atea Pharmaceuticals Inc. (AVIR) Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir

Apr 17, 2025 07:02AM Atea Pharmaceuticals (AVIR) Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Mar 26, 2025 01:58PM Atea Pharmaceuticals Inc. (AVIR) Highlights Actions Underway to Enhance Shareholder Value

Mar 6, 2025 04:11PM Aviragen Therapeutics (AVIR) Misses Q4 EPS by 5c

Feb 24, 2025 07:04AM Atea Pharmaceuticals Inc. (AVIR) Appoints Arthur S. Kirsch to its Board

Dec 4, 2024 07:00AM Atea Pharmaceuticals (AVIR) Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus

Nov 7, 2024 04:26PM Aviragen Therapeutics (AVIR) Tops Q3 EPS by 6c

Sep 13, 2024 07:01AM Atea Pharmaceuticals Inc. (AVIR) Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 Did Not Meet Primary Endpoin

Sep 13, 2024 06:57AM Atea Pharmaceuticals Inc. (AVIR) Halted, News Pending

Aug 28, 2024 07:01AM Atea Pharmaceuticals (AVIR) Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway

Aug 12, 2024 04:05PM Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) to Equalweight, 'HCV opportunity comes into focus, while COVID outcome remains uncertain'

Aug 7, 2024 04:13PM Aviragen Therapeutics (AVIR) Tops Q2 EPS by 18c